CD274 and non-small cell lung carcinoma: Some patients underwent durable and profound responses lasting 15.4 months and beyond, endorsing the use of this combination therapy throughout the disease course.[53] Additionally, lifileucel as a monotherapy in ICI‐treated metastatic NSCLC patients reached an ORR at 21.4% (6/28).[54] Among responders, two patients were PD‐L1 negative, among which one had an ongoing complete response at 26.3 months.